Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2− Metastatic Breast Cancer 2025

Hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer accounts for approximately two-thirds of all breast cancers. The treatment landscape for HR+/HER2− metastatic breast cancer has evolved in recent years, with multiple new therapies demonstrating...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Katarzyna J. Jerzak, Aalok Kumar, Jean-François Boileau, Nathaniel Bouganim, Christine Brezden-Masley, Jeffrey Q. Cao, David W. Cescon, Stephen Chia, Scott Edwards, Anil Abraham Joy, Kara Laing, Nathalie LeVasseur, Sasha Lupichuk, Sandeep Sehdev, Christine Simmons, Marc Webster, Karen A. Gelmon, Mita Manna, on behalf of patient advocacy, Breast Cancer Canada
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2026-02-01
Saila:	Current Oncology
Gaiak:	HR+ HER2− metastatic advanced breast cancer Canadian consensus recommendations evidence-based REAL Alliance
Sarrera elektronikoa:	https://www.mdpi.com/1718-7729/33/2/106
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!